The survival and the incidence of treatment cessation according to the model. Overall survival at 10 years in the 4 strategies simulated by the current model (A) and the survival for the imatinib-first strategy simulated by the current model in comparison with the results of the IRIS trial and the imatinib arm of the ENESTnd trial (B). Cumulative incidence of treatment cessation in the 4 strategies simulated by the MR4.5 model (C) and the MR4.0 model (D).